Some short-sellers bought media coverage for bad mouthing IBM. They are wrong, since bigger guys disagree with their opinions. Also market has shift IBM from sell to buy mode.
Buy IBM all the way up to $195 for target $215 before year end or so!
Dog of Dow says that the previous dog of Dow components will be shine next year.2013 is the dog year for IBM. Its price keeps falling while market up. This doom day for IBM will be gone soon!
Buy at this level, and you will be much richer!
ARIAD price target lowered to $9 from $28 at Leerink
Leerink believes there remains a place for ARIAD's leukemia drug Iclusig in patients in the salvage setting despite continued cardiovascular toxicity findings. The firm thinks the benefit of Iclusig is likely to outweigh risk in the salvage setting and keeps an Outperform rating on shares of ARIAD, despite lowering its price target for shares to $9 from $28.